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Male Clinical
Efficacy and safety of the coadministration of
tadalafil once daily with finasteride for 6
months in men with lower urinary tract symp-
toms and prostatic enlargement secondary to
benign prostatic hyperplasia. A Casabé, CG
Roehrborn, LF Da Pozzo, S Zepeda, RJ Hender-
son, S Sorsaburu, C Henneges, DG Wong, L
Viktrup. J Urol 2014;191:727–33.
Editorial Comment: Since the launch of the
5-alpha reductase inhibitor ﬁnasteride in 1992,
medical management of lower urinary tract symp-
toms (LUTSs) secondary to benign prostatic
hyperplasia (BPH) has continued to evolve. Today,
in addition to 5-alpha reductase inhibitors, both
alpha-blockers and phosphodiesterase type-5
inhibitors are approved for the treatment of men
with BPH/LUTS. Recently, various guidelines
have recommended combination of a 5-alpha
reductase inhibitor with an alpha-blocker to
achieve earlier and greater LUTS improvement
when compared with monotherapy of either group
of drug alone. However, there is an increased risk
of sexual dysfunction related to this combination
of therapies that constructs the major concern
related to this treatment option.
Tadalaﬁl is a long-acting phosphodiesterase
type-5 inhibitor that has recently been approved for
the treatment BPH/LUTS. Clinical studies have
demonstrated that tadalaﬁl 5 mg once daily results
in clinically signiﬁcant improvements in BPH/
LUTSwith the additional beneﬁt of restoring erec-
tile function in patients with concomitant erectile
dysfunction. In order to assess whether the combi-
nation of a 5-alpha reductase inhibitorwith tadalaﬁl
may result in early LUTS improvement with fewer
sexual side effects, Casabé et al. conducted a ran-
domized, double-blind, placebo-controlled, multi-
center study. The authors randomized 695 men to
receive either tadalaﬁl 5 mg or placebo once daily
co-administered with ﬁnasteride 5 mg once
daily over the course of 26 weeks. The results of
this study demonstrated that tadalaﬁl 5 mg
coadministered with ﬁnasteride resulted in more
rapid and more signiﬁcant LUTS improvement
when compared with ﬁnasteride coadministered
with placebo. Moreover, the ﬁnasteride/tadalaﬁl
combination signiﬁcantly improved erectile
function in men who had erectile dysfunction
prior to initiation of treatment. These results
support that once daily coadministration of
tadalaﬁl with ﬁnasteride can be the treatment of
choice for men with LUTS and erectile dysfunc-
tion symptoms.
Ege Can Serefoglu, MD, FECSM
Tadalafil for prevention of erectile dysfunction
after radiotherapy for prostate cancer: The
Radiation Therapy Oncology Group [0831]
randomized clinical trial. TM Pisansky, SL
Pugh, RE Greenberg, N Pervez, DR Reed, SA
Rosenthal, RB Mowat, A Raben, MK
Buyyounouski, LA Kachnic, DW Bruner. JAMA
2014;311:1300–7.
Editorial Comment: All currently available pros-
tate cancer treatment modalities include the risk
of erectile dysfunction (ED), and a signiﬁcant
amount of prostate cancer patients experiences ED
after radiotherapy. In this multicenter, stratiﬁed,
placebo-controlled, double-blind, parallel-group
study, Pisansky et al. aimed to determine whether
tadalaﬁl 5 mg once daily maintains spontaneous
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erectile function in men treated with radiotherapy
for prostate cancer. The authors randomized 242
men whose prostate cancer was treated with radia-
tion to receive either daily tadalaﬁl 5 mg treatment
or placebo for 24 weeks. The International Index
of Erectile Function (IIEF) was administered
before radiotherapy, at week 2, week 4, between
weeks 20 and 24, between weeks 28 and 30, and 1
year thereafter. IIEF did not demonstrate any sta-
tistically signiﬁcant difference between the two
groups. The authors concluded that daily use of
tadalaﬁl 5 mg compared with placebo did not
result in improved erectile function, and they did
not recommend this treatment modality to
prevent ED in these patients.
Ege Can Serefoglu, MD, FECSM
Sildenafil citrate improves erectile function
after castration in a rat model. JP Mulhall, N
Verma, S Deveci, R Tal, K Kobylarz, A Müller.
BJU Int 2014;113:656–61.
Editorial Comment: Surgical or chemical castra-
tion is used as a standard therapy for metastatic
cancer, and it is associated with impaired erectile
function due to the imbalance between smooth
muscle and collagen in the corpora cavernosa.
Taking the beneﬁcial effect of sildenaﬁl citrate on
penile tissue after cavernous nerve injury into con-
sideration,Mulhall et al. assessedwhether thismol-
ecule would result in preservation of erectile
function and tissue structure in the rat penis after
castration. They used 60 male Sprague-Dawley
rats divided into three groups (sham, bilateral
orchidectomy, and bilateral orchidectomy +
sildenaﬁl). The authors measured maximum
intracavernosal pressure–mean arterial blood pres-
sure (ICP/MAP) ratio, evaluated smooth muscle–
collagen (SM–C) ratio, and deﬁned apoptotic
indices (AIs) on 7th and 28th postoperative days.
The authors demonstrated that the ICP/MAP ratio
was highest in the sham group, whereas it was
lowest in the orchidectomy group. Rats treated
with sildenaﬁl after orchidectomy showed statisti-
cally signiﬁcant improvements in their ICP/MAP
ratio over the corresponding control groups;
however, their ICP/MAP ratio was lower than that
of rats in the sham group. On the other hand,
the authors could not detect any signiﬁcant differ-
ences in either SM–C ratio or AIs between the
orcidectomy and orchidectomy + sildenaﬁl groups.
Considering the increased ICP/MAP ratios in the
treatment group, the authors concluded that daily
treatment with sildenaﬁl may prevent or reduce the
damage to penile tissue after castration.
Ege Can Serefoglu, MD, FECSM
Lingual mucosal graft in treatment of Peyronie
disease. EA Salem, EH Elkady, A Sakr, AM
Maarouf, L Bendary, S Khalil, A Shahin, H Kamel.
Urology 2014;84:1374–7.
Editorial Comment: The optimal graft material
to be used in the penile incision and grafting
surgery for the treatment of Peyronie Disease
(PD) continues to be a matter of debate. Although
various materials have been used for grafting pro-
cedures (i.e., dermis, vein, cadaveric and bovine
pericardium, dura mater, synthetic materials, and
porcine small intestine submucosal extracellular
matrix), there is no consensus about the ideal graft
in patients with PD. Synthetic grafts are associated
with inﬂammatory and infectious complications,
whereas tissue-engineered grafts are costly. In
spite of their favorable outcomes low cost, the high
incidence of harvest site side effects of autologous
grafts limit their wide spread use.
In this study, Salem et al. evaluated the use of
lingual mucosa graft (LMG) in 17 patients with
PD. The angle of deformity ranged from 45 to 70
degrees with a mean angle of 60 degrees. All
patients were assessed with the International Index
of Erectile Function-5 (IIEF-5) preoperatively.
Postoperative evaluation included IIEF-5 score
and the assessment of penile deformity after 1
month, and then every 3 months until 18 months.
Donor site complications were also reported. The
authors found only mild and transient donor site
complications such as pain and numbness. Fifteen
of the 17 patients (88.2%) had straightening of the
penis at follow-up. Two patients had mild residual
curvature of the penis (20 degrees) which was
treated conservatively. Erectile function was main-
tained in 16 patients; 94% of patients reported
satisfaction with the procedure. This report is the
ﬁrst study to analyze the use of LMG for PD, and
excellent results were obtained. The advantages of
this technique include easy accessibility of the
tongue mucosa compared with the deeply seated
buccal mucosa, lower costs compared with “off the
shelf” graft materials, and lower donor site mor-
bidity. These results must be analyzed with caution
because of the short follow-up period, small
sample size, and single institution nature of the
study. As all patients in this series had curvature
less than 70 degrees, the applicability of this tech-
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nique to more severe curvature is unclear. Further
studies on lingual grafts for PD are warranted.
David Jacques Cohen, MD
The relationship between total testosterone
levels and prostate cancer: A review of the con-
tinuing controversy. J Klap, M Schmid, KR
Loughlin. J Urol 2015;193:403–14.
EditorialComment:Formany years, testosterone
was believed to play a major role in the develop-
ment of prostate cancer (PCa). In the last decades,
serious controversies have emerged about the true
relationship between testosterone and PCa. In this
review article, the authors looked for the answers to
the twomain questions: (i) Is there any link between
serum testosterone and incidence, grade, and
aggressiveness of PCa? (ii) What is the true risk
of testosterone replacement therapy (TRT) in
patients with primary hypogonadism that already
treated PCa or are in active surveillance program?
The authors reviewed the literature from 1994
to 2014 and analyzed the results of 45 articles were
selected and analyzed, of which 18 and 17 showed
a relationship between PCa and low and high total
testosterone, respectively. On the other hand, 10
studies showed no relationship between testoster-
one and PCa.
The discrepancy in these results may be attrib-
utable to biological and/or methodological factors.
The ﬁrst biological explanation is the Saturation
Model, which states PCa cells are sensitive to ﬂuc-
tuations from very low doses of testosterone. As
levels increase, the androgen receptors become
saturated, and additional testosterone does not
inﬂuence androgen-driven changes in prostate
tissue growth. Additional biological factors that
must be considered include the functional activity
of androgen receptors in prostate tissue and the
theoretical role of intraprostatic testosterone and
dihidrotestosterone. Finally, the effects of estro-
gens on carcinogenesis of PCa are incompletely
elucidated; some of the biological effects of testos-
terone on the prostate may be mediated by
aromatization of testosterone to estradiol.
The main methodological failure of this analysis
is that only three of the 45 studies collected blood
for testosterone assay in the morning and only one
study collected two or more samples. Thus, testos-
terone identiﬁed as low in some studies may have
been normal on another day or at another hour
during the day. No deﬁnitive conclusions can be
made about the relationship about testosterone
and PCa from these trials. Additional trials must
be done to overcome the methodological obstacles
and clarify biological hypothesis.
There are relatively few papers on TRT in
patients previously treated for PCa. It is advisable
that patients considering TRT after treatment for
PCa be extensively counseled on the controversies
surrounding TRT in this situation; patients who
wish to proceed should sign informed consent
forms and be followed very closely with serial
digital rectal examination and PSAs. There are
only two studies of TRT in patients in active sur-
veillance for PCa with contradictory results. TRT
may be considered in such cases, but it must be
made clear that the long-term risks are unknown,
and there exists the possibility of PCa progression
from this treatment.
David Jacques Cohen, MD
Male Basic Science
Oxidative stress associated with middle aging
leads to sympathetic hyperactivity and
downregulation of soluble guanylyl cyclase in
corpus cavernosum. FH Silva, C Lanaro, LO
Leiria, RL Rodrigues, AP Davel, MA Claudino,
HA Toque, E Antunes. Am J Physiol Heart Circ
Physiol 2014;307:H1393–400.
Editorial Comment: The role of sympathetic
neurotransmission in erectile dysfunction (ED) is
increasingly becoming a hot topic in sexual medi-
cine, particularly in the ﬁeld of penile rehabilitation
program after radical prostatectomy. The leading
theory dictates that nitric oxide (NO) is a negative
modulator of sympathetic neurotransmission.
Vasoconstriction and increased corporal smooth
muscle tone produced by sympathetic signals are
enhanced by impaired NO bioavailability. This
enhancement of hypercontractility in cavernosal
tissues and their supplying arteries promotes the
development of ED.
In the present article, the authors investigated
the role of oxidative stress in the pathogenesis of
ED focusing on its link with the development of an
aberrant sympathetic neurotransmission in the
erectile tissue. The authors report that ED in
middle-aged rats (10 months old) is associated
with up-regulation of mRNA coding for
tyrosine hydroxylase (a speciﬁc marker for sym-
pathetic nerve), and increased phenylephrine-
induced contractions in organ bath studies, along
with alpha1-adrenoceptor-mediated cavernosal
vasoconstriction. Furthermore, decreased expres-
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sion of soluble guanylyl cyclic in cavernosal smooth
muscle was also reported.
NADPH oxidase is localized in sympathetic
nerve ﬁber endings, which indicates a superoxide-
mediated mechanism in neurovascular control.
Interestingly, the present study reported that the
treatment with the NADPH oxidase inhibitor
“apocynin” normalized the reactive oxygen species
(ROS) levels and restored the tyrosine hydroxylase
mRNA expression and hence the sympathetic
cavernosal contractions. These results demonstrate
a role for the elevated oxidative stress contributing
to ED in middle-aged rats. Excess of superoxide
could promote a higher tyrosine hydroxylase
expression, whereas in the latter, it reduces NO
bioavailability and sGC expression, which in turn
causes ED by mechanisms involving impairment of
relaxations and facilitation of contraction. Based on
these data, the authors concluded that antioxidant
therapies might represent an interesting approach
to manage ED in aging population.
While the results presented provide a clear
message on the role of oxidative stress in sympa-
thetic hyperactivity in aging induced ED, this
study is not devoid of limitations. The major study
limitations include the lack of an in vivo evaluation
of erectile function and the “age” of the rat
selected for mimicking the middle age human con-
dition. Without an in vivo evaluation, it not pos-
sible to evaluate the degree of erectile function
impairment in the rats. Moreover, a 10-month-old
rat is equivalent to a 28-year-old man, and older
animals (20–22 months) should have been selected
to study the age-dependent effects on erectile
function.
Fabio Castiglione, MD
Inhibition of ninjurin 1 restores erectile
function through dual angiogenic and
neurotrophic effects in the diabetic mouse.
GN Yin, MJ Choi, WJ Kim, MH Kwon, KM
Song, JM Park, ND Das, KD Kwon, D Batbold,
GT Oh, GY Koh, KW Kim, JK Ryu, JK Suh. Proc
Natl Acad Sci U S A 2014;111:E2731–40.
Editorial Comment: Much progress over the past
two decades has improved our understanding of
the molecular pathophysiology of erectile dysfunc-
tion (ED). However, few medical therapies
have been developed since the introduction of
phosphodiesterase inhibitors in 1998.Nonetheless,
our improved understanding of erectile function
and dysfunction has yielded new drug targets over
the past several years, including extracellular-
related kinase, guanylate cyclase, the RhoA/Rho-
kinase pathway, and the endothelin and angiotensin
receptors. In 1996, nerve injury-induced protein 1
(Ninjurin 1, Ninj1) was identiﬁed as an induced
factor after axotomy in neurons and Schwann cells
that promote neurite extension [1]. Ninj1 is a cell
surface molecule that has roles in regulating
nervous and vascular systems. In 2013, Yin et al.
examined the role of Ninj1 in the penis and found
that Ninj1 levels are upregulated after murine
penile cavernous nerve injury, and that Ninj1 inhi-
bition results in increased neuroﬁlament and
endothelial cell proliferation [2]. These ﬁndings
established a foundation for Ninj1 as a novel thera-
peutic target for cavernous nerve injury-induced
ED.
Rather than merely focusing on surgical nerve
injury, the same group more recently evaluated the
role of Ninj1 in mice with diabetes-induced ED,
ﬁnding that Ninj1 inhibition facilitates erectile
function in this setting as well [3]. In this study, Yin
et al. evaluated the efﬁcacy of Ninj1-neutralizing
antibody and knockout ofNinj1 in preserving erec-
tile function in streptozotocin (STZ)-treated mice.
STZ results in a diabetic condition via pancreatic
beta cell toxicity. First, the authors demonstrated
increased expression of Ninj1 in the penis of dia-
beticmice and inmouse cavernous endothelial cells
(MCECs) exposed to high glucose conditionsmim-
icking diabetes mellitus. They then evaluated erec-
tile function after intracavernosal injection of
Ninj1-blocking antibody in the STZ mice, observ-
ing restoration of erectile function to baseline in
these mice. However, this positive effect on erectile
function was short-lived, indicating that optimiza-
tion of Ninj1 inhibition is necessary. Ninj1 inhibi-
tion also resulted in proliferation of cavernous
endothelial cells, and decreased apoptosis in these
cells, supporting an angiogenic effect. The authors
demonstrated that Ninj1-mediated angiogenic
effects arise from signaling via the angiopoietin 1
(Ang1)-tyrosine kinase with Ig and epidermal
growth factor homology domain-2 (Tie2) pathway
by blocking this pathway. The Ang1–Tie2 pathway
is essential in generating functional, nonleaky
blood vessels. Ninj1 inhibition was also found to
lower levels of reactive oxygen species (ROS), a
further positive ﬁnding given that high levels of
ROS induce apoptosis.
When evaluating the effects of Ninj1 inhibition
on nerve content, the authors found not only more
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neuroﬁlaments in mouse penis undergoing Ninj1
inhibition but higher levels of neuronal nitric oxide
synthase (nNOS) in Ninj1-inhibited penis. Preser-
vation of nNOS is signiﬁcant given that nNOS
release from nerve terminals initiates penile erec-
tion. These effects on nerve preservation were
mediated by secretion of nerve growth factors
(NGFs) including brain-derived neurotrophic
factor, NGF, and neurotrophin 3, which were
markedly upregulated during Ninj1 inhibition.
The authors then expanded their investigations
to Ninj1 knockout mice, which had preserved erec-
tile function even in the setting of STZ treatment,
further conﬁrming a role for Ninj1 in ED patho-
genesis. Finally, while the presence of Ninj1 and
Ang1-Tie2 are important in regulation of diabetes-
induced ED, the entire pathway has not yet been
described. To identify Ninj1 target genes, the
authors used gene expression microarray technolo-
gies inMCECs exposed to high and normal glucose
conditions, and with and without knockdown of
Ninj1 using siRNA, ﬁnding numerous genes that
may play a role in the pathway.
This study is signiﬁcant in that it describes a
novel pathway regulating both angiogenesis as well
as neurogenesis in the penis and suggests a novel
therapeutic target in the setting of ED. The
detailed mechanisms by which Ninj1 is induced,
the components of the Ninj1 pathway, and the
mechanisms of angiogenesis and neurogenesis
mediated by this pathway remain to be deﬁned. In
addition, the role of theNinj1 pathway in humans is
currently unknown. It will indeed be interesting to
see what future investigations yield in determining
whether Ninj1 is a bona ﬁde regulator of human
erectile function, and therefore a target for future
therapies.
Alexander W. Pastuszak, MD, PhD
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Male Mental Health
Relations between trait impulsivity, behavioral
impulsivity, physiological arousal, and risky
sexual behavior among young men. KJ
Dereﬁnko, JR Peters, TA Eisenlohr-Moul, EC
Walsh, ZW Adams, DR Lynam. Arch Sex Behav
2014;43:1149–58.
EditorialComment:The outcomes of risky sexual
behavior have a long-term negative impact on indi-
viduals’ private and public lives. Young adults are at
particular risk for these outcomes. A sample of 135
undergraduate men (Mage = 19.5) participated in an
experimental study aimed at assessing the unique
predictive value of impulsivity-related traits,
behavioralmarkers of risk taking, and physiological
reactivity in three distinct indicators of risky sex:
number of sexual partners, having sex with strang-
ers, and irregular condom use. For the ﬁrst time,
three approaches, usually considered individually
in the study of sexual risk taking, were incorporated
in a single design: (i) trait markers of risky sex
(evaluated by self-report), (ii) behavioralmarkers of
risky decisions (measured by experimental means,
usually involving some level of awareness), and (iii)
physiological reactivity to emotional stimuli (mea-
sured experimentally, involving no awareness
by the participant). In this study, participants
answered to a set of self-report measures assessing
impulsivity (negative urgency, positive urgency,
and sensation seeking), participated in a behavioral
risk taking task (the Ballon Analogue Risk Task
[BART]) and in a reward-seeking Go/No-Go task,
and underwent a psychophysiological evaluation
(skin conductance reactivity) to pleasant vs.
unpleasant stimulation. Scores on these markers
were used as predictors of thementioned indicators
of risky sex. Sensation seeking (β = 0.19) and risk
taking on the BART (β = 0.18) signiﬁcantly pre-
dicted number of sexual partners (P < 0.05). Also,
sensation seeking (β = 0.60), risk taking on the
BART (β = 0.52), and skin conductance reactivity
to both types of stimuli (β = 0.53) predicted the
risk of ever having sex with a stranger (P < 0.05).
Finally, negative urgency predicted irregular
condom use (β = 0.14, P < 0.05). Prevention pro-
grams (e.g., HIV prevention) are expected to
beneﬁt from this kind of multimethod assessment.
Sexual risk indicators are differently impacted by
trait and physiological markers; preventive strate-
gies should be designed accordingly.
Joana Carvalho, PhD
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Midlife menopause: Male partners talking. L
Liao, S Lunn, M Baker. Sex Relation Ther
2015;30:167–80.
Editorial Comment: How do men appraise
menopause? A lot has been written about women’s
perceptions of menopause and so little about the
male perspectives. In this qualitative study, eight
heterosexual male partners (Mage = 51.5) described
their perceptions about midlife menopause. Male
partners’ views of menopause were analyzed
through thematic analysis (TA); this method is
particularly suitable when no structured empirical
data exist. Participants were interviewed by a white
female psychologist in her early thirties, either at
the participant’s home or the interviewer’s work-
place. The following general topics emerged:
Female Transformation
Menopause was seen as a process, something to be
entered into and completed. During this process,
women were described as emotionally charged.
Simultaneously, some men appraised menopause
as a chance of personal growth and a period in
which women can expand into a more liberating
life.
A Shared Process
Men recognized that menopause is a shared
process implying a transition to a new dyadic stage.
Yet men felt they were pulled unprepared into
this process. They felt helplessness. They were
expected to support their partners but were left
unsupported by the system. Also, men alluded to
some positive and negative outcomes in sex. Some
expressed preoccupation about the partner’s loss
of libido. But, on the other hand, menopause was
also regarded as positive (e.g., liberation from the
contraceptive constraints).
A Sex Taboo
Menopause was referred as a taboo topic possibly
because of its overlap with sexual phenomena.
Men do not talk about it because they feel embar-
rassed. Menopause was regarded as a sign of
diminished female sexuality. Men felt they had to
respect the partners’ privacy rather than discuss
this topic. Finally, most interviewees agreed that
there is a lack of general knowledge on this subject;
menopause was deﬁned as a nebulous area and not
many options exist to clarify men’s doubts.
Women seem to be the only target of information
and support.
In all, men lack knowledge on menopause
because of a social etiquette that deﬁnes who is
expected to receive such information. Yet men
want to know more about menopause as they too
have to go through this process. Although this was
a ﬁrst attempt to understand men’s perspectives
about menopause, ﬁndings support the role of pro-
fessionals in assisting male partners of menopausal
women.
Joana Carvalho, PhD
LGB/Transgender
Social connection, relationships, and older
lesbian and gay people. Barrett C, Whyte C,
Comfort J, Lyons A, Crameri, P. Sex Relation
Ther 2015;30:131–42.
Editorial Comment: Many sexual medicine
issues arise in older patients and clients. Yet the
issues cannot be addressed successfully if the
person experiencing them does not (i) present to
the practitioner in the ﬁrst place or (ii) is fearful of
fully disclosing their speciﬁc situation. For older
lesbian and gay people, both of these challenges to
treatment and care present a larger barrier than
for their heterosexual counterparts. Barrett et al.
provide ground-breaking exploratory research
into the issues which often prevent older lesbian
and gay persons from seeking medical assistance
or being forthcoming with their situation. The
research appropriately uses qualitative methods to
delve deep for a robust understanding of how these
older lesbian and gay people have come to manage
their lives in today’s world, one that is massively
different from the one in which they grew up. In a
word, discrimination is still very much a perceived
reality for older lesbian and gay persons, perhaps
more so than for younger generations. The person
we are today is the sum of a lifetime of experiences.
The sexual medicine practitioner would beneﬁt
from reading the article to gain a more robust
and lived historical understanding of their older
lesbian and gay patients or clients, leading to
better treatment and care.
Christopher Fisher, PhD, MA, AA, BS
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